BMC
ALNY icon

Bear Mountain Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bear Mountain Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$257 – 188
2025
Q1 		$257 Buy
+1
New +$257 ﹤0.01% 307

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bear Mountain Capital's ALNY Position: Q2 2025 in Review

Bear Mountain Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 1 share — an estimated $257 sold.

Bear Mountain Capital first reported a position in ALNY in Q1 2025 and held it in 1 quarter. The position peaked at $257 in Q1 2025. 653 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • Bear Mountain Capital reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bear Mountain Capital sold 1 Alnylam Pharmaceuticals share in Q2 2025, an estimated $257.
  • Bear Mountain Capital first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Bear Mountain Capital's Alnylam Pharmaceuticals position peaked at $257 in Q1 2025.
  • 653 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Bear Mountain Capital's 13F filing for Q2 2025, filed 23 Jul 2025.